Skip to contentZ
Zivo Bioscience, Inc.
Z
ZIVOZivo Bioscience, Inc. Q1 2023 · 10-Q
Revenue$0.00$0.00— vs Q1 2022 Net Income-$1.97M-$1.97MN/M vs Q1 2022 EPS, diluted—
Operating Income-$1,970,174N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Zivo Bioscience, Inc. · CIK 1101026 · Engraved from SEC EDGAR
Operating Cash Flow-$2,128,973N/M ended Mar 31, 2023 · filed May 10, 2023 · 40 d after period end